Covaxin Phase III trial data approved by DCGI expert panel, shows efficacy of 77.8%

June 22: The Subject Expert Committee (SEC) has approved Bharat Biotech phase III trials efficacy data. According to the data submitted, Covaxin has shown 77.8 percent efficacy. The Phase 3 trials for the vaccine were conducted on 25,800 subjects. It is said to be a significant boost for the company as it was only given emergency approval, and now it has got the approval of the phase III trial data. Bharat Biotech delayed submitting the data as they have been doing trials on a massive scale of the vaccination.

India^‘s indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV). The vaccine is developed using Whole-Virion Inactivated Vero Cell derived platform technology. Inactivated vaccines do not replicate and are therefore unlikely to revert and cause pathological effects. Analysis from the National Institute of Virology indicates that vaccine-induced antibodies can neutralize the UK variant strains and other heterologous strains.